Table 3.
Multivariate linear regression for the association of serum DPP4 concentration with thyroid function and TRAb in the GD group.
| Model 1 |
Model 2 |
Model 3 |
||||
|---|---|---|---|---|---|---|
| Variables | Standardized β (95% CI) | p | Standardized β (95% CI) | p | Standardized β (95% CI) | P |
| FT3 | 0.451 (0.266, 0.636) | <.001 | 0.436 (0.243, 0.629) | .001 | _ | _ |
| FT4 | 0.475 (0.293, 0.658) | <.001 | 0.467 (0.273, 0.660) | <.001 | _ | _ |
| TSH | −0.229 (−0.430, −0.027) | .026 | −0.217 (−0.423, −0.012) | .038 | _ | _ |
| TRAb | 0.524 (0.348, 0.700) | <.001 | 0.436 (0.246, 0.625) | <.001 | 0.265 (0.026, 0.504) | .030 |
Note: Model 1 unadjusted; Model 2 adjusted for age, sex and BMI; Model 3 adjusted for age, gender, BMI, FT3, lymphocyte count, AST and HOMA-IR. BMI: body mass index; FT3: free triiodothyronine; FT4: free thyroxine; TRAb: anti-thyrotropin receptor antibodies; AST: aspartate aminotransferase; HOMA-IR: homeostasis model assessment of insulin resistance; DPP-4: dipeptidyl peptidase-4; GD: Graves’ disease.